SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Nov 6, 2017

SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Nov. 6, 2017 · CIK: 0001390478 · Accession: 0001193125-17-334513

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-220592

Referenced dates: November 6, 2017

Date
November 6, 2017
Author
/s/ Keith D. Pisani
Form
CORRESP
Company
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)

Letter

(212) 318-6053

keithpisani@paulhastings.com

November 6,

VIA EDGAR AND BY COURIER

Ms. Christine Westbrook

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re: Galena Biopharma, Inc.

Amendment No. 2 to Registration Statement on Form S-4

Filed November 6, 2017

File No. 333-220592

Ladies and Gentlemen:

On behalf of Galena Biopharma, Inc. (“Galena”), we are transmitting for filing one copy of Amendment No. 3 (the “Amendment”) to Galena’s above-referenced Registration Statement on Form S-4, as amended (the “Registration Statement”) marked to show the changes made to Amendment No. 2 to the Registration Statement filed with the Securities and Exchange Commission (the “Commission”) on November 6, 2017.

This Amendment is being filed in response to comments with respect to Amendment No. 2 to the Registration Statement received from the Commission (the “Staff”) by letter dated November 6, 2017. The numbering of the paragraphs below corresponds to the numbering of the Staff’s comments which, for your convenience, we have incorporated into this response letter in italics. Page references in the text of Galena’s responses correspond to the page numbers of the Amendment. Capitalized terms used herein but not defined herein shall have the meanings assigned to them in the Amendment.

S-4/A filed on 11/6/17

Exhibit 5.1 Legal Opinion, page II-6

1. We note you have assumed the authority, legal right and power of each of the officers and other persons and entities signing or whose signatures appear upon each of said documents. It is not appropriate to assume that officers have the legal authority to sign the identified documents as this is a conclusion of law which is a necessary requirement of the legality opinion. Please file a legal opinion that does not assume the officers have the authority sign the identified documents.

Paul Hastings LLP | 200 Park Avenue | New York, NY 10166

t: +1.212.318.6000 | www.paulhastings.com

Galena has revised the Registration Statement to include a revised legal opinion as Exhibit 5.1.

2. Additionally, we note that in rendering your opinion, you limited your review to the documents identified without stating whether you reviewed all documents you deemed necessary for the purposes of providing your opinion. Please file a legal opinion that clarifies that you reviewed all documents you considered necessary for the purpose of rendering your opinion.

Galena has revised the Registration Statement to include a revised legal opinion as Exhibit 5.1.

* * *

If you have any questions, or if it would expedite your review in any way, please do not hesitate to contact the undersigned at (212) 318-6053 or Thomas Pollock at (415) 856-7047.

We thank the Staff in advance for its assistance.

Sincerely,
/s/ Keith D. Pisani

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 (212) 318-6053

 keithpisani@paulhastings.com

 November 6,
2017

 VIA EDGAR AND BY COURIER

Ms. Christine Westbrook

 Division of
Corporation Finance

 U.S. Securities and Exchange Commission

 100 F Street, N.E.

 Washington, D.C. 20549

Re:
Galena Biopharma, Inc.

Amendment No. 2 to Registration Statement on Form S-4

Filed November 6, 2017

File No. 333-220592

 Ladies and Gentlemen:

 On behalf of Galena Biopharma, Inc. (“Galena”), we are
transmitting for filing one copy of Amendment No. 3 (the “Amendment”) to Galena’s above-referenced Registration Statement on Form S-4, as amended (the “Registration Statement”)
marked to show the changes made to Amendment No. 2 to the Registration Statement filed with the Securities and Exchange Commission (the “Commission”) on November 6, 2017.

 This Amendment is being filed in response to comments with respect to Amendment No. 2 to the Registration Statement received from the Commission (the “Staff”) by letter dated
November 6, 2017. The numbering of the paragraphs below corresponds to the numbering of the Staff’s comments which, for your convenience, we have incorporated into this response letter in italics. Page references in the text of
Galena’s responses correspond to the page numbers of the Amendment. Capitalized terms used herein but not defined herein shall have the meanings assigned to them in the Amendment.

S-4/A filed on 11/6/17

Exhibit 5.1 Legal Opinion, page II-6

1.
We note you have assumed the authority, legal right and power of each of the officers and other persons and entities signing or whose signatures appear upon each of
said documents. It is not appropriate to assume that officers have the legal authority to sign the identified documents as this is a conclusion of law which is a necessary requirement of the legality opinion. Please file a legal opinion that does
not assume the officers have the authority sign the identified documents.

 Paul Hastings LLP | 200 Park Avenue
| New York, NY 10166

 t: +1.212.318.6000 | www.paulhastings.com

 Galena has revised the Registration
Statement to include a revised legal opinion as Exhibit 5.1.

2.
Additionally, we note that in rendering your opinion, you limited your review to the documents identified without stating whether you reviewed all documents you
deemed necessary for the purposes of providing your opinion. Please file a legal opinion that clarifies that you reviewed all documents you considered necessary for the purpose of rendering your opinion.

Galena has revised the Registration Statement to include a revised legal opinion as Exhibit 5.1.

*    *    *

 If you have any questions, or if it would expedite your review in any way, please do not hesitate to contact the undersigned at (212) 318-6053 or Thomas Pollock at
(415) 856-7047.

 We thank the Staff in advance for its assistance.

Sincerely,

 /s/ Keith D. Pisani

Keith D. Pisani

 for PAUL HASTINGS LLP

 Enclosures